Yungjin Pharm Co Ltd (003520.KS)
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs. Yungjin Pharm. Co., Ltd. was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Company Info
Highlights
₩416.99B
₩188.97B
₩60.03B
₩1,823.00 - ₩2,790.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₩10,000 in Yungjin Pharm Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
Yungjin Pharm Co Ltd (003520.KS) has returned 14.69% so far this year and 2.47% over the past 12 months. Over the last ten years, 003520.KS has returned -0.90% per year, falling short of the S&P 500 benchmark, which averaged 11.51% annually.
003520.KS
- YTD
- 14.69%
- 1M
- 6.79%
- 6M
- 9.88%
- 1Y
- 2.47%
- 3Y*
- -14.52%
- 5Y*
- -15.96%
- 10Y*
- -0.90%
^GSPC (Benchmark)
- YTD
- 7.06%
- 1M
- 5.28%
- 6M
- 5.00%
- 1Y
- 14.38%
- 3Y*
- 16.95%
- 5Y*
- 14.32%
- 10Y*
- 11.51%
Monthly Returns
The table below presents the monthly returns of 003520.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Dec 1995, the average daily return (also called the expected return) is 0.04%, while the average monthly return is 1.22%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.61% | 0.74% | -4.86% | 5.37% | 8.09% | 0.45% | 2.48% | 14.19% | |||||
| 2024 | -4.47% | 0.49% | 5.39% | -1.63% | -3.07% | 1.95% | 21.77% | -2.16% | -5.42% | 2.34% | -13.07% | -5.11% | -6.45% |
| 2023 | 10.31% | -9.62% | -9.41% | 0.34% | -4.92% | -11.96% | 0.41% | 0.20% | -7.26% | -8.91% | -3.82% | 5.46% | -34.62% |
| 2022 | -11.63% | 3.53% | 7.44% | -4.62% | -15.22% | -13.79% | -1.66% | -5.61% | -21.84% | 3.42% | 19.85% | -0.31% | -38.56% |
| 2021 | -16.04% | -4.44% | -4.81% | 5.54% | -4.32% | -5.48% | -5.63% | -2.35% | -6.85% | -6.76% | -13.01% | 29.66% | -34.20% |
| 2020 | -15.84% | -10.22% | -3.19% | 2.99% | 5.51% | 4.74% | 18.30% | 4.44% | 19.35% | -12.90% | 12.83% | 0.50% | 21.27% |
| 2019 | 9.09% | 2.31% | 0.45% | -1.50% | -16.31% | -7.65% | -11.34% | -0.11% | 4.23% | 14.10% | 21.72% | 2.00% | 11.62% |
| 2018 | 11.85% | -10.59% | -5.92% | 3.87% | -4.55% | -9.28% | 0.67% | 7.09% | 5.24% | -34.52% | 10.33% | -2.46% | -32.35% |
| 2017 | -18.14% | 14.96% | -1.57% | 4.65% | 46.20% | -9.20% | -15.59% | 9.08% | -7.27% | -8.26% | 1.91% | -3.09% | -0.45% |
| 2016 | 19.48% | -4.72% | 44.95% | 127.60% | 50.62% | -2.90% | -7.69% | -0.46% | 15.35% | -29.44% | -4.00% | 5.00% | 314.08% |
| 2015 | 8.43% | 7.42% | 12.50% | 4.97% | 0.28% | -6.67% | 35.71% | -5.26% | -5.79% | 12.04% | 3.95% | -10.13% | 63.22% |
| 2014 | -0.30% | 3.28% | 6.65% | -0.27% | -2.72% | -5.31% | -7.67% | 2.56% | -0.93% | -10.38% | -1.40% | -7.12% | -22.32% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 003520.KS is 50, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Yungjin Pharm Co Ltd (003520.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Yungjin Pharm Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Yungjin Pharm Co Ltd was 98.99%, occurring on Oct 29, 2008. The portfolio has not yet recovered.
The current Yungjin Pharm Co Ltd drawdown is 95.73%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.99% | May 9, 1996 | 3039 | Oct 29, 2008 | — | — | — |
| -32.55% | Dec 4, 1995 | 77 | Mar 29, 1996 | 23 | May 6, 1996 | 100 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Yungjin Pharm Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Yungjin Pharm Co Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -1,247.6%.
Valuation
The Valuation section provides an overview of how Yungjin Pharm Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 003520.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 003520.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 003520.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003520.KS has a P/S ratio of 2.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 003520.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003520.KS has a P/B value of 4.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |